FinTok
developed by Fiadm s.r.o. · future of webapps
Ostatné · PCVX
silný nákup
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | -2,14 | -2,70–-1,67 | -1,56 | −37,1 % |
| budúci štvrťrok | -2,05 | -2,87–-0,86 | -1,80 | −13,9 % |
| tento rok | -8,20 | -9,41–-6,19 | -5,63 | −45,6 % |
| budúci rok | -7,22 | -11,65–-4,96 | -8,20 | +12,0 % |
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | – | – | +0,0 % |
| budúci štvrťrok | – | – | +0,0 % |
| tento rok | – | – | +0,0 % |
| budúci rok | 87,1 mil. | – | +0,0 % |
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Wassil JamesChief Operating Officer | predaj | 163 863 | 09.09. |
| Jodar LuisOfficer | odmena v akciách | – | 04.09. |
| Wassil JamesChief Operating Officer | predaj | 212 352 | 01.09. |
| Wassil JamesChief Operating Officer | uplatnenie opcií | 12 038 | 01.09. |
| Dhaliwal Harpreet S.Officer | predaj | 935 068 | 05.08. |
| Dhaliwal Harpreet S.Officer | uplatnenie opcií | 421 430 | 05.08. |
| Guggenhime AndrewPresident | predaj | 538 879 | 03.08. |
| Wassil JamesChief Operating Officer | predaj | 121 195 | 03.08. |
| Wassil JamesChief Operating Officer | uplatnenie opcií | 12 038 | 03.08. |
| Guggenhime AndrewPresident | uplatnenie opcií | 53 500 | 03.08. |
| Pickering Grant EChief Executive Officer | predaj | 1,0 mil. | 27.07. |
| Pickering Grant EChief Executive Officer | uplatnenie opcií | 32 882 | 27.07. |
Slávni investori: Ray Dalio · 0.0 %
FMR, LLC14,01 %
Jupiter Topco LLC12,07 %
T. Rowe Price Investment Management, Inc.8,20 %
Blackrock Inc.8,11 %
RA Capital Management, L.P.7,71 %
Wellington Management Group, LLP4,71 %
Vanguard Portfolio Management LLC4,43 %
Vanguard Capital Management LLC4,27 %
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
K tomuto aktívu zatiaľ nemáme odporúčanie.
Žiadne predikcie.
Spoločnosť Vaxcyte (PCVX) oznámila pozitívne výsledky z fázy 3 klinických skúšok VAX-31, ktoré splnili všetky primárne ciele. Táto správa viedla k rastu akcií a je dôležitá pre investorov v biotechnologickom sektore.